Clinical Trials Browser

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Completed

130 enrolled

Plasma cell

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase 3 Active not recruiting

310 enrolled 18 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04624906 2026-02-04

BRAWM

Phase 2 Active not recruiting

63 enrolled

Lymphoid

Waldenstrom Macroglobulinemia

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

122 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT05023980 2026-01-22

BRUIN CLL-313

Phase 3 Active not recruiting

309 enrolled

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04223765 2026-01-20

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Phase 1 Recruiting

20 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05508867 2026-01-20

MK-4280A-008

Phase 2 Completed

203 enrolled

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Phase 1/2 Recruiting

25 enrolled

Hematopoietic and Lymphoid System Neoplasm

NCT06425302 2026-01-08

GOLSEEK-2

Phase 2 Active not recruiting

90 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT06970743 2026-01-07

CaDAnCe-303

Phase 3 Recruiting

150 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1 Active not recruiting

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Phase 3 Recruiting

260 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT06043713 2025-12-19

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Phase 1 Recruiting

24 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

150 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Phase 1 Completed

31 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06241456 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Recruiting

351 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

19 enrolled

Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase 3 Recruiting

400 enrolled

Lymphoid

Lymphoma, Follicular

NCT03352765 2025-12-04

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

Phase 1 Active not recruiting

28 enrolled

Lymphoid

Lymphoma

Clinical Trials

CaDAnCe-302

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

EPCORE™FL-2

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

EPCORE™ NHL-2

waveLINE-003

TERZO

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

GLOBRYTE

ZEBRA

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

FT819 in Subjects With B-cell Malignancies

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

OLYMPIA-1

SEQUOIA

CRISTALLO

Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

BRAZAN

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

BRAWM

FIL_A-BEGEV

BRUIN CLL-313

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

MK-4280A-008

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

GOLSEEK-2

CaDAnCe-303

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

FT576 in Subjects With Multiple Myeloma

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients